Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06770855 · ClinicalTrials.gov registry record · NA
Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Not yet
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT06770855 is a NA study that has not yet begun recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 23 participants.
The verdict
NCT06770855, a NA study, has not yet begun recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response/stable disease after at least 6 months of immune checkpoint blockade-based therapy for metastatic clear cell RCC. The investigators hypothesize that patients who undergo total consolidative MPDT followed by systemic therapy discontinuation will have a 12-month treatment-free survival rate of 32% compared to a null hypothesis of 13%
Interventions
- PROCEDURE Total consolidative MPDT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2028-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06770855
The ClinicalTrials.gov registry entry for NCT06770855 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Total consolidative MPDT is the first listed.
NCT06770855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06770855 about?
NCT06770855 is a clinical study titled "Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)". This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response/stable disease after at least 6 months of immune checkpoint blockade-based ...
What is the current status of trial NCT06770855?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 23 participants. The study started on 2026-06-30. Estimated completion is 2028-09.
What interventions are being tested in trial NCT06770855?
The interventions under investigation include: Total consolidative MPDT (PROCEDURE).
Who is sponsoring clinical trial NCT06770855?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.